At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KROS Keros Therapeutics, Inc.
Closed 01-13 16:00:00 EST
12.82
-1.74
-11.95%
盘后13.29
+0.47+3.67%
19:42 EST
High14.10
Low12.35
Vol2.31M
Open14.00
D1 Closing14.56
Amplitude12.02%
Mkt Cap519.30M
Tradable Cap453.46M
Total Shares40.51M
T/O29.62M
T/O Rate6.54%
Tradable Shares35.37M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.